DeItaone reports: JPMorgan Chase, Morgan Stanley, and Canaccord Genuity raise AbbVie (ABBV) price target; Leerink Partners raises Agios Pharmaceuticals (AGIO) price target
JPMorgan Chase raised its price target on AbbVie (ABBV) from $280 to $285, Morgan Stanley from $278 to $296, and Canaccord Genuity from $282 to $290. Additionally, Leerink Partners raised its price target on Agios Pharmaceuticals (AGIO) from $62 to $73.
Source:X@DeItaone · Source Link
Disclaimer: This content reflects only the author’s personal views and does not constitute any investment or financial advice. If you discover any content that violates regulations,Click to Report
24H Trending
-
1
What Is LBY? An Analysis of the Libonomy and Lobby Projects and Their Prospects
-
2
A Guide to the Legality of Cryptocurrency Trading Apps and How to Identify Legitimate Platforms
-
3
OKX OKX App Feature Overview and Step-by-Step Guide to Withdrawing Funds to Alipay via Fiat Currency Trading
-
4
What Is MOC Coin? An Analysis of Moss Coin, Money On Chain, and Their Trading Channels
-
5
Wall Street analysts are bullish on natural gas producer Expand Energy, SM Energy, and oilfield services provider SLB, citing strong Q2 results and growth prospects
-
6
Analysis of BBT Token Value: Current Status of the BitBook Project and Investment Risk Assessment
-
7
Exchanging USDC for Chinese Yuan: How-To Guide and Important Notes
-
8
What Is WNRG? An Analysis of the Wrapped Energi Token and Where to Trade It
-
9
OXBULL (OXB) Token Analysis: Project Positioning, Current Status, and Future Prospects
-
10
DHS Coin: Analysis of the Current Status and Future Prospects of the Dirham Crypto (DHS) Project
Markets Today
Recommended Reading











